论文部分内容阅读
目的:探究结核性胸膜炎患者给予胸腔注入尿激酶的治疗方法和疗效。方法:选取2014年3月至2015年8月收治的86例结核性胸膜炎患者进行治疗,随机分组,实验组46例患者在胸腔注入尿激酶的治疗,对照组40例患者给予常规的抗结核、引流胸水治疗,比较治疗效果。结果:和对照组相比,实验组患者胸液的平均时间明显更短,抽液总量更多,胸膜厚度更薄,胸膜黏连率低,病情好转率高,差异显著(P<0.05)。结论:结核性胸膜炎患者给予胸腔注入尿激酶的治疗,可有助于身体的康复,治疗时间短,效果显著,并发症少,减轻患者的身体不适,值得在临床上广泛应用。
Objective: To investigate the treatment and efficacy of pleural injection of urokinase in patients with tuberculous pleurisy. Methods: A total of 86 patients with tuberculous pleurisy admitted from March 2014 to August 2015 were randomly divided into treatment group (n = 46), experimental group (n = 46) received urokinase therapy, and control group (n = 40) Drainage of hydrothorax, the treatment effect. Results: Compared with the control group, the average time of pleural effusion in the experimental group was significantly shorter, the volume of fluid extraction was more, the thickness of the pleura was thinner, the rate of pleural adhesions was lower and the rate of improvement was significantly higher (P <0.05) . Conclusion: The treatment of tuberculous pleurisy by injecting urokinase into the chest cavity can help the body to recover. The treatment time is short, the effect is obvious, the complication is less and the patient’s discomfort is alleviated. It is worth to be widely used clinically.